Literature DB >> 20637651

Impaired hepatic removal of interleukin-6 in patients with liver cirrhosis.

Reiner Wiest1, Johanna Weigert, Josef Wanninger, Markus Neumeier, Sabrina Bauer, Sandra Schmidhofer, Stefan Farkas, Marcus N Scherer, Andreas Schäffler, Jürgen Schölmerich, Christa Buechler.   

Abstract

Systemic concentrations of interleukin-6 (IL-6) are elevated in patients with liver cirrhosis, and impaired hepatic uptake of IL-6 was suggested to contribute to higher levels in these patients. To test this hypothesis IL-6 was measured in portal venous serum (PVS), hepatic venous serum (HVS) and systemic venous serum (SVS) of 41 patients with liver cirrhosis and four patients with normal liver function. IL-6 was higher in PVS than HVS of all blood donors and about 43% of portal vein derived IL-6 was extracted by the healthy liver, and 6.3% by the cirrhotic liver demonstrating markedly impaired removal of IL-6 by the latter. Whereas in patients with CHILD-PUGH stage A IL-6 in HVS was almost 25% lower than in PVS, in patients with CHILD-PUGH stage C IL-6 was similarly abundant in the two blood compartments. Ascites is a common complication in cirrhotic patients and was associated with higher IL-6 levels in all blood compartments without significant differences in hepatic excretion. Hepatic venous pressure gradient did not correlate with the degree of hepatic IL-6 removal excluding hepatic shunting as the principal cause of impaired IL-6 uptake. Furthermore, patients with alcoholic liver cirrhosis had higher IL-6 in all blood compartments than patients with cryptogenic liver cirrhosis. Aetiology of liver cirrhosis did not affect hepatic removal rate indicating higher IL-6 synthesis in patients with alcoholic liver cirrhosis. In summary, the current data provide evidence that impaired hepatic removal of IL-6 is explained by hepatic shunting and liver dysfunction in patients with liver cirrhosis partly explaining higher systemic levels. Copyright Â
© 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20637651     DOI: 10.1016/j.cyto.2010.06.013

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  12 in total

1.  STAT3 is a key transcriptional regulator of cancer stem cell marker CD133 in HCC.

Authors:  Sarani Ghoshal; Bryan C Fuchs; Kenneth K Tanabe
Journal:  Hepatobiliary Surg Nutr       Date:  2016-06       Impact factor: 7.293

2.  Pro-atherosclerotic markers and cardiovascular risk factors one year after liver transplantation.

Authors:  Mario Reis Alvares-da-Silva; Claudia Pinto Marques Souza de Oliveira; José Tadeu Stefano; Hermes V Barbeiro; Denise Barbeiro; Francisco G Soriano; Alberto Queiroz Farias; Flair José Carrilho; Luiz Augusto Carneiro D'Albuquerque
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

Review 3.  Adiponectin, a key adipokine in obesity related liver diseases.

Authors:  Christa Buechler; Josef Wanninger; Markus Neumeier
Journal:  World J Gastroenterol       Date:  2011-06-21       Impact factor: 5.742

4.  Adiponectin upregulates hepatocyte CMKLR1 which is reduced in human fatty liver.

Authors:  Josef Wanninger; Sabrina Bauer; Kristina Eisinger; Thomas S Weiss; Roland Walter; Claus Hellerbrand; Andreas Schäffler; Akiko Higuchi; Kenneth Walsh; Christa Buechler
Journal:  Mol Cell Endocrinol       Date:  2011-11-18       Impact factor: 4.102

5.  Serum proinflammatory cytokines and nutritional status in pediatric chronic liver disease.

Authors:  Daniele Santetti; Maria Inês de Albuquerque Wilasco; Cristina Toscani Leal Dornelles; Isabel Cristina Ribas Werlang; Fernanda Urruth Fontella; Carlos Oscar Kieling; Jorge Luiz Dos Santos; Sandra Maria Gonçalves Vieira; Helena Ayako Sueno Goldani
Journal:  World J Gastroenterol       Date:  2015-08-07       Impact factor: 5.742

Review 6.  Changes of Intestinal Functions in Liver Cirrhosis.

Authors:  Hiroshi Fukui; Reiner Wiest
Journal:  Inflamm Intest Dis       Date:  2016-03-08

7.  Increased HCMV seroprevalence in patients with hepatocellular carcinoma.

Authors:  Quentin Lepiller; Manoj K Tripathy; Vincent Di Martino; Bernadette Kantelip; Georges Herbein
Journal:  Virol J       Date:  2011-10-27       Impact factor: 4.099

Review 8.  Adipokines in Liver Cirrhosis.

Authors:  Christa Buechler; Elisabeth M Haberl; Lisa Rein-Fischboeck; Charalampos Aslanidis
Journal:  Int J Mol Sci       Date:  2017-06-29       Impact factor: 5.923

9.  Proinflammatory Cytokines (IL-1α, IL-6) and Hepatocyte Growth Factor in Patients with Alcoholic Liver Cirrhosis.

Authors:  Andrzej Prystupa; Paweł Kiciński; Jarosław Sak; Anna Boguszewska-Czubara; Anna Toruń-Jurkowska; Wojciech Załuska
Journal:  Gastroenterol Res Pract       Date:  2015-08-20       Impact factor: 2.260

10.  Peripheral and Hepatic Vein Cytokine Levels in Correlation with Non-Alcoholic Fatty Liver Disease (NAFLD)-Related Metabolic, Histological, and Haemodynamic Features.

Authors:  Luisa Vonghia; Thea Magrone; An Verrijken; Peter Michielsen; Luc Van Gaal; Emilio Jirillo; Sven Francque
Journal:  PLoS One       Date:  2015-11-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.